Fixed-Dose Trial in Early Parkinson's Disease (PD)
Public ClinicalTrials.gov record NCT04201093. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, 27-Week Trial to Evaluate the Efficacy, Safety, and Tolerability of Two Fixed Doses of Tavapadon in Early Parkinson's Disease (TEMPO-1 TRIAL)
Study identification
- NCT ID
- NCT04201093
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- AbbVie
- Industry
- Enrollment
- 529 participants
Conditions and interventions
Conditions
Interventions
- Tavapadon Drug
- Placebo Drug
Drug
Eligibility (public fields only)
- Age range
- 40 Years to 80 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 12, 2019
- Primary completion
- Jun 27, 2024
- Completion
- Jun 27, 2024
- Last update posted
- Jul 27, 2025
2019 – 2024
United States locations
- U.S. sites
- 27
- U.S. states
- 18
- U.S. cities
- 27
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Birmingham, Alabama | Birmingham | Alabama | 35233 | — |
| Little Rock, Arkansas | Little Rock | Arkansas | 72205 | — |
| Fountain Valley, California | Fountain Valley | California | 92708 | — |
| Los Angeles, California | Los Angeles | California | 90048 | — |
| Pasadena, California | Pasadena | California | 91105 | — |
| Englewood, Colorado | Englewood | Colorado | 80113 | — |
| Adventura, Florida | Adventura | Florida | 33180 | — |
| Boca Raton, Florida | Boca Raton | Florida | 33486 | — |
| Tampa, Florida | Tampa | Florida | 33613 | — |
| Augusta, Georgia | Augusta | Georgia | 30912 | — |
| Savannah, Georgia | Savannah | Georgia | 31406 | — |
| Chicago, Illinois | Chicago | Illinois | 60612 | — |
| Kansas City, Kansas | Kansas City | Kansas | 66160 | — |
| Scarborough, Maine | Scarborough | Maine | 04074 | — |
| Boston, Massachusetts | Boston | Massachusetts | 02215 | — |
| East Lansing, Michigan | East Lansing | Michigan | 48824 | — |
| Las Vegas, Nevada | Las Vegas | Nevada | 89106 | — |
| Asheville, North Carolina | Asheville | North Carolina | 28806 | — |
| Durham, North Carolina | Durham | North Carolina | 27705 | — |
| Columbus, Ohio | Columbus | Ohio | 43221 | — |
| Toledo, Ohio | Toledo | Ohio | 43614 | — |
| Philadelphia, Pennsylvania | Philadelphia | Pennsylvania | 19107 | — |
| Georgetown, Texas | Georgetown | Texas | 78628 | — |
| Houston, Texas | Houston | Texas | 77030 | — |
| Lubbock, Texas | Lubbock | Texas | 79410 | — |
| Burlington, Vermont | Burlington | Vermont | 05401 | — |
| Virginia Beach, Virginia | Virginia Beach | Virginia | 23456 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 50 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04201093, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 27, 2025 · Synced Jul 23, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04201093 live on ClinicalTrials.gov.